ArticleJAMA network open2024
Travel-Time Disparities in Access to Proton Beam Therapy for Cancer Treatment.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Residential location shapes initial prostate cancer care in Korea (2010-2020): A nationwide stage- and risk-stratified study.Investigative and clinical urology · 2026Article
- Proton Therapy Utilization Among Adult Cancer Patients.International journal of particle therapy · 2026Article
- Comparative outcomes of proton and photon therapy in the management of malignant peripheral nerve sheath tumors.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Telehealth Infrastructure for Cancer Care in the United States.Scientific data · 2026Article
- Understanding financial toxicity in cancer care through a social-ecological lens.Current opinion in oncology · 2026Review
- Reversed sequence radiation therapy for treatment of primary central nervous system choriocarcinoma prioritizing for bleeding control: A case report.SAGE open medical case reports · 2026Article
- Organ Preservation in Esophageal Cancer: Current Strategies, Challenges, and Future Directions.Cancers · 2025Review
- Risk calculator for long-term survival prediction of spinal chordoma versus chondrosarcoma: a nationwide analysis.Journal of neuro-oncology · 2025Article
- Factors associated with participation in a proton therapy clinical trial: a cross-sectional survey of Danish patients with head and neck cancer.Acta oncologica (Stockholm, Sweden) · 2025Article
- Implementation of a novel pencil beam scanning Bragg peak FLASH technique to a commercial treatment planning system.Medical physics · 2025Article
- Geographical Discrepancy in Medical Care Access Among Children, Adolescents, and Young Adults With Cancer in Japan, 2016-2019.Cancer science · 2025Article
- Health Disparities and Inequities in the Utilization of Proton Therapy for Prostate Cancer.Cancers · 2024Review
- Review
- Impact of proton vs. photon radiotherapy on overall survival in the management of spinal chondrosarcoma and mortality risk prediction: A nationwide analysis.Neuro-oncology advancesArticle
- Development of a Patient Decision Aid for the DAHANCA 35 Proton Radiotherapy Trial: An Iterative Development Process with User-Centered Design Elements.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Importance: Proton beam therapy is an emerging radiotherapy treatment for patients with cancer that may produce similar outcomes as traditional photon-based therapy for many cancers while delivering lower amounts of toxic radiation to surrounding tissue. Geographic proximity to a proton facility is a critical component of ensuring equitable access both for indicated diagnoses and ongoing clinical trials. Objective: To characterize the distribution of proton facilities in the US, quantify drive-time access for the population, and investigate the likelihood of long commutes for certain population subgroups. Design, Setting, and Participants: This population-based cross-sectional study analyzed travel times to proton facilities in the US. Census tract variables in the contiguous US were measured between January 1, 2017, and December 31, 2021. Statistical analysis was performed from September to November 2023. Exposures: Drive time in minutes to nearest proton facility. Population totals and prevalence of specific factors measured from the American Community Survey: age; race and ethnicity; insurance, disability, and income status; vehicle availability; broadband access; and urbanicity. Main Outcomes and Measures: Poor access to proton facilities was defined as having a drive-time commute of at least 4 hours to the nearest location. Median drive time and percentage of population with poor access were calculated for the entire population and by population subgroups. Univariable and multivariable odds of poor access were also calculated for certain population subgroups. Results: Geographic access was considered for 327 536 032 residents of the contiguous US (60 594 624 [18.5%] Hispanic, 17 974 186 [5.5%] non-Hispanic Asian, 40 146 994 [12.3%] non-Hispanic Black, and 195 265 639 [59.6%] non-Hispanic White; 282 031 819 [86.1%] resided in urban counties). The median (IQR) drive time to the nearest proton facility was 96.1 (39.6-195.3) minutes; 119.8 million US residents (36.6%) lived within a 1-hour drive of the nearest proton facility, and 53.6 million (16.4%) required a commute of at least 4 hours. Persons identifying as non-Hispanic White had the longest median (IQR) commute time at 109.8 (48.0-197.6) minutes. Multivariable analysis identified rurality (odds ratio [OR], 2.45 [95% CI, 2.27-2.64]), age 65 years or older (OR, 1.09 [95% CI, 1.06-1.11]), and living below the federal poverty line (OR, 1.22 [1.20-1.25]) as factors associated with commute times of at least 4 hours. Conclusions and Relevance: This cross-sectional study of drive-time access to proton beam therapy found that disparities in access existed among certain populations in the US. These results suggest that such disparities present a barrier to an emerging technology in cancer treatment and inhibit equitable access to ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.